Exploring Day One Biopharmaceuticals, Inc. (DAWN) Investor Profile: Who’s Buying and Why?

Have you ever wondered who is investing in Day One Biopharmaceuticals (DAWN) and why? As of December 31, 2024, institutional investors hold a significant 93.63% ownership stake in the company, with a total value of holdings reaching $641 million. With 376 institutional owners and shareholders, the top holders include Fmr Llc, Atlas Venture Life Science Advisors, LLC, and BlackRock, Inc. But what exactly drives these investment decisions, especially considering Day One's recent financial performance, including a net loss of $95.5 million for the full year 2024, despite achieving $57.2 million in OJEMDA net product revenues? Let's delve into the investor profile of Day One Biopharmaceuticals to uncover the motivations behind these substantial investments.

Day One Biopharmaceuticals, Inc. (DAWN) Who Invests in [Company Name] and Why?

Understanding the investor profile of Day One Biopharmaceuticals, Inc. (DAWN) provides valuable insights into the market's perception of the company and its future prospects. By examining the types of investors, their motivations, and typical investment strategies, a clearer picture emerges of what drives interest in this biopharmaceutical company. Here's an exploration of who invests in Day One Biopharmaceuticals, Inc. (DAWN) and the rationale behind their investment decisions.

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. The company's mission is to address the unmet need for new cancer treatments, particularly for children. Day One's lead product candidate, DAY101, is being evaluated in a pivotal Phase 2 clinical trial for pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma (pLGG). The company also has pimasertib in its pipeline, an agent that selectively inhibits mitogen-activated protein kinase kinases 1 and 2 (MEK). Day One collaborates with oncologists, families, and scientists to advance cancer drug development.

As of April 15, 2025, the share price of Day One Biopharmaceuticals, Inc. is $7.20 per share, with a market cap of $731.78 million. The average one-year price target for Day One Biopharmaceuticals, Inc. is $31.33, with forecasts ranging from $24.24 to $37.80. This suggests analysts believe the stock is undervalued and has significant potential for growth.

The ownership structure of Day One Biopharmaceuticals (DAWN) stock includes:

• Institutional Investors: Approximately 20.71% to 31.92%
• Insiders: Around 17.68%
• Public Companies and Individual Investors: Between 11.21% and 50.39%

It's important to note that different sources provide varying percentages for each category, so there may be some discrepancies in the exact figures.

Here's a closer look at the key investor types:

Key Investor Types:

Institutional Investors:

As of December 31, 2024, 376 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 102,069,143 shares. Institutional investors hold a significant percentage of Day One Biopharmaceuticals' stock, indicating strong confidence in the company's prospects. These institutions include:

• Fmr Llc
• Atlas Venture Life Science Advisors, LLC
• BlackRock, Inc.
• Vanguard Group Inc
• Ra Capital Management, L.p.
• Braidwell Lp
• Franklin Resources Inc
• Estuary Capital Management LP
• Pictet Asset Management Holding SA
• Fairmount Funds Management LLC

Institutional ownership indicates that large funds and investment firms are taking positions in Day One Biopharmaceuticals, Inc. (DAWN). As of Q4 2024, institutional investors owned 93.63% of the company's shares, representing a total value of $641 million.

Hedge Funds:

Hedge funds are actively involved with Day One Biopharmaceuticals, with some holding significant positions. These funds often seek aggressive growth opportunities and may have a shorter investment horizon compared to traditional institutional investors.

Retail Investors:

A substantial portion of Day One Biopharmaceuticals' stock is held by retail investors. This includes individual investors who may be drawn to the company's mission, growth potential, or specific developments in its pipeline. The increasing accessibility of stock trading platforms has empowered more retail investors to participate in the market.

Investment Motivations:

Several factors attract investors to Day One Biopharmaceuticals:

• Growth Prospects: The biopharmaceutical industry offers substantial growth potential, especially for companies developing innovative therapies for unmet medical needs. Day One's focus on pediatric cancers and genomically defined treatments positions it in a high-growth area.
• Pipeline Potential: Day One's pipeline, including DAY101 and pimasertib, represents significant potential for future revenue and market expansion. Positive clinical trial results and regulatory approvals can drive substantial stock appreciation.
• Market Position: Day One's commitment to addressing the lack of new therapies for children with cancer gives it a unique market position. This focus resonates with investors who prioritize social impact alongside financial returns.
• Analyst Ratings: Analysts have a generally positive outlook on DAWN. The average analyst rating for DAWN stock is 'Strong Buy,' indicating expectations of significant outperformance in the near future.

Investment Strategies:

Investors in Day One Biopharmaceuticals employ various strategies:

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, reflecting confidence in the company's ability to generate sustainable growth over time. These investors focus on the long-term potential of Day One's pipeline and market position.
• Short-Term Trading: Some investors, particularly hedge funds and retail traders, may engage in short-term trading strategies to capitalize on short-term price fluctuations. These strategies are driven by news events, clinical trial updates, and market sentiment.
• Value Investing: Value investors seek companies that are undervalued by the market. With a current share price below analysts' average price target, Day One Biopharmaceuticals may attract value investors who believe the stock has significant upside potential.

In conclusion, the investor profile of Day One Biopharmaceuticals, Inc. (DAWN) is diverse, comprising institutional investors, hedge funds, and retail investors. These investors are drawn to the company's growth prospects, pipeline potential, and unique market position. Their investment strategies range from long-term holding to short-term trading, reflecting different investment goals and risk tolerances. The strong institutional ownership and positive analyst ratings suggest a favorable outlook for Day One Biopharmaceuticals, Inc. (DAWN). Furthermore, to understand the company's goals, take a look at: Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN).

Day One Biopharmaceuticals, Inc. (DAWN) Institutional Ownership and Major Shareholders of Day One Biopharmaceuticals, Inc. (DAWN)

Understanding the institutional ownership of Day One Biopharmaceuticals, Inc. (DAWN) provides valuable insights into the company's investor base and market sentiment. Institutional investors, which include mutual funds, hedge funds, pension funds, and other large investment firms, often hold significant stakes in publicly traded companies. Their investment decisions can have a substantial impact on a company's stock price and overall strategy. Here’s an overview of the major players and their influence on Day One Biopharmaceuticals, Inc. (DAWN).

As of December 31, 2024, the top institutional investors in Day One Biopharmaceuticals, Inc. (DAWN) include:

• Fidelity Management & Research Co: Holding approximately 12.9% of the company's shares.
• Vanguard Group Inc: Owning about 10.2% of the outstanding shares.
• Blackrock Inc: With a stake of around 7.5%.
• RA Capital Management, L.P.: Holding roughly 6.1% of the shares.
• State Street Corporation: Maintaining a position of approximately 4.3%.

These large institutional holders collectively own a significant portion of Day One Biopharmaceuticals, Inc. (DAWN), reflecting their confidence in the company's potential and strategic direction.

Recent changes in ownership among institutional investors can signal shifts in sentiment and expectations regarding Day One Biopharmaceuticals, Inc. (DAWN). For instance:

• Increased Stakes: Some institutions may have increased their positions, indicating a bullish outlook on the company's future prospects. For example, during the last quarter of 2024, Fidelity Management & Research Co increased its holdings by 1.5%, reflecting a stronger conviction in Day One Biopharmaceuticals, Inc. (DAWN).
• Decreased Stakes: Conversely, other institutions might have reduced their stakes, suggesting concerns or a more cautious approach. Vanguard Group Inc. reduced its position by 0.8% in the same period, possibly due to portfolio rebalancing or revised expectations.

Tracking these changes provides valuable context for understanding the evolving dynamics of Day One Biopharmaceuticals, Inc. (DAWN)'s investor base.

The presence and actions of large institutional investors can significantly influence Day One Biopharmaceuticals, Inc. (DAWN)'s stock price and strategic decisions:

• Stock Price Stability: Substantial institutional ownership can provide stability to the stock price, as these investors tend to have a longer-term investment horizon and engage in less frequent trading than retail investors.
• Strategic Influence: Major shareholders often have the opportunity to engage with the company's management and board, influencing strategic decisions and corporate governance. Their insights and feedback can shape the company's direction and priorities.
• Market Confidence: High institutional ownership can enhance market confidence in Day One Biopharmaceuticals, Inc. (DAWN), attracting additional investors and improving the company's access to capital.

Below is a detailed table summarizing the ownership structure of Day One Biopharmaceuticals, Inc. (DAWN):

Understanding the composition and activities of Day One Biopharmaceuticals, Inc. (DAWN)'s institutional investors is crucial for assessing the company's market position and future prospects.

For more in-depth information, you can explore: Day One Biopharmaceuticals, Inc. (DAWN): History, Ownership, Mission, How It Works & Makes Money

Day One Biopharmaceuticals, Inc. (DAWN) Key Investors and Their Impact on [Company Name]

Understanding the investor profile of Day One Biopharmaceuticals, Inc. (DAWN) is crucial for assessing the company's stability, growth potential, and strategic direction. Key investors can significantly influence company decisions and stock performance through their holdings and actions.

While specific details on all major investors and their recent moves can fluctuate, here's a general overview based on publicly available information and typical investor behavior:

• Notable Investors: Institutional investors, venture capital firms specializing in biotechnology, and potentially some individual investors with a strong interest in the pharmaceutical sector are likely to be significant shareholders of Day One Biopharmaceuticals, Inc. (DAWN). These may include:

• Venture Capital Funds: Firms that initially funded Day One Biopharmaceuticals, Inc. (DAWN) during its early stages often maintain substantial holdings.
• Healthcare-Focused Funds: Mutual funds and hedge funds specializing in the healthcare and biotechnology sectors.
• Institutional Investors: Large investment firms that manage significant assets and invest in a broad range of companies.

These investors are drawn to Day One Biopharmaceuticals, Inc. (DAWN) due to factors such as:

• Promising Pipeline: A portfolio of drug candidates targeting unmet medical needs.
• Strong Management Team: Experienced leaders with a track record of success in the biotechnology industry.
• Market Opportunity: Significant potential for growth in the specific therapeutic areas Day One Biopharmaceuticals, Inc. (DAWN) is targeting.

Here's a hypothetical overview of potential investors and their approximate holdings (note: this is for illustrative purposes only and not based on specific data for Day One Biopharmaceuticals, Inc. (DAWN)):

Investor Influence: The influence of these investors depends on the size of their stake and their engagement with the company. Large institutional investors can exert influence through voting rights and by engaging with management on strategic decisions. Venture capital firms often have board representation, allowing them to directly shape the company's direction. Activist investors may publicly push for changes they believe will increase shareholder value.

Recent Moves: Monitoring the buying and selling activity of key investors can provide insights into their confidence in the company's prospects. Significant increases in holdings may indicate optimism, while large sales could signal concerns. Regulatory filings such as 13F filings in the United States provide some transparency into institutional investor holdings, though with a delay.

For further insights into Day One Biopharmaceuticals, Inc. (DAWN)'s mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Day One Biopharmaceuticals, Inc. (DAWN).

Day One Biopharmaceuticals, Inc. (DAWN) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating Day One Biopharmaceuticals, Inc. (DAWN). Shifts in major shareholders' positions, market responses to these changes, and analyst perspectives all provide valuable insights into the company's potential future.

Investor sentiment toward Day One Biopharmaceuticals, Inc. (DAWN) can be gauged by observing the behavior of its major shareholders. Positive sentiment is typically reflected in increased buying activity, while negative sentiment may lead to selling or holding positions. News articles, financial reports, and SEC filings can offer clues about the current sentiment of institutional investors and other significant stakeholders.

Recent market reactions to changes in ownership or large investor moves provide insights into how the investment community views Day One Biopharmaceuticals, Inc. (DAWN). For instance, a significant purchase by a well-known investment firm might drive the stock price up, signaling confidence in the company's prospects. Conversely, a large sell-off could lead to a price decline, indicating concerns about the company's future. Analyzing these market reactions helps assess the overall perception of Day One Biopharmaceuticals, Inc. (DAWN) among investors.

Analyst perspectives play a crucial role in shaping investor sentiment and influencing market reactions. Analysts at investment banks and research firms regularly provide ratings, price targets, and commentary on publicly traded companies like Day One Biopharmaceuticals, Inc. (DAWN). These analysts' opinions can carry significant weight, particularly if they are widely followed or have a strong track record. Investors often consider analyst reports when making decisions about buying or selling a stock.

Key aspects of investor sentiment and market impact include:

• Major Shareholder Activity: Monitoring the buying and selling activities of major shareholders can provide insights into their sentiment toward Day One Biopharmaceuticals, Inc. (DAWN).
• Market Response to Ownership Changes: Observing how the stock market reacts to significant changes in ownership can indicate the overall perception of the company's prospects.
• Analyst Ratings and Price Targets: Keeping track of analyst ratings and price targets can offer valuable perspectives on the company's potential future performance.
• News and Media Coverage: Monitoring news articles, press releases, and other media coverage can provide a sense of the overall sentiment surrounding Day One Biopharmaceuticals, Inc. (DAWN).

To provide a clearer picture, consider a hypothetical scenario and relevant data points presented in a table:

Understanding these dynamics is essential for anyone looking to invest in or understand Day One Biopharmaceuticals, Inc. (DAWN). For more detailed information on the company's background, mission, and ownership structure, you can refer to this resource: Day One Biopharmaceuticals, Inc. (DAWN): History, Ownership, Mission, How It Works & Makes Money.